APOE and Alzheimer disease: The trial is still ongoing, looking for a shred of hopeful outcome (ID NCT01760005).129 Aducanumab, another monoclonal antibody currently in phase III of clinical trials, (NCT02477800 and NCT02484547) produced some promising results in phase I study (NCT01677572), which was performed on a group of mild and prodromal AD patients with and without APOE4 mutations.